K65R frequently emerges within 1-6 weeks of tenofovir monotherapy in macaques

HIV Treat Bull - Vol. 7, No. 5, May 2006

Jeffrey Johnson and colleagues from CDC Atlanta and the University of California performed longitudinal resistance tests on plasma sample from eleven SIV-infected macaques, receiving 30mg/kg tenofovir daily using a test sensitive to 0.2% mutant virus.

K65R was detected after one week in 4 animals, and by week 6 in another 4 animals. All animals had a one-week treatment interruption at week 6. The remaining 3 macaques developed K65 by week 9.

Mutations were originally at frequencies too low to be detected by population sequencing (~1-10%) in 5 or 11 animals, but increased to sequence-detectable levels 2 to 4 weeks after their initial identification by the real-time PCR assay.

The researchers concluded that ’despite the high fitness cost conferred by the K65R mutation, resistance can emerge rapidly’, and that ‘this may have implications for people who become infected with HIV while using tenofovir pre-exposure prophylaxis.

COMMENT

The emergence of K65R over such short periods in most of these animals, is too rapid to be detected by any real world monitoring within human trials.

This increases the importance of treatment programmes to be established in trials of tenofovir pre-exposure prophylaxis (PrEP), especially as the human trials are proposed in high-risk populations.

It would be very important to know whether the addition of FTC provided any level of protective benefit, as anecdotally, Truvada is being used instead of tenofovir therapy, when used off-label as chemoprophylaxis.

Ref: Johnson J, Van Rompay K, Delwart E et al. Rapid emergence of drug-resistant SIV in tenofovir-treated macaques: implications for tenofovir chemoprophylaxis against HIV. 13th CROI, Denver, 2006. Abstract 609.

2008-03-10
IB060705-26

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.